testosterone cypionate cycle

The following are adverse reactions are listed by frequency of their development, starting with the most frequent. The frequency of adverse testosterone cypionate cycle reactions is estimated as follows: very common ( > 1/10); common ( > 1/100, <1/10); sometimes ( > 1/1000, <1/100); rare ( > 1/10000, <1/1000); very rare (<1/10000), including isolated reports: Mental disorders : Sometimes : confusion, agitation, hallucinations Rare : psychotic disorder, insomnia. Very rare : increased libido, hypersexuality CNS : Often : headache, drowsiness , dizziness, sometimes : movement disorders; rare : drowsiness, paresthesia; Very rare : increased daytime sleepiness, sudden sleep. From the sensory organs : rarely : impaired vision, “blurred vision”, tinnitus. cardio-vascular system : Sometimes : hypotension, orthostatic hypotension (very rarely leading to fainting); rare :. pericardial effusion, constrictive pericarditis, tachycardia, bradycardia, arrhythmias very rare : fibrosis of the heart valves, reversible pallor of the fingers on the hands and feet caused by hypothermia ( especially in patients with Raynaud’s phenomenon in history). The respiratory system, organs, thoracic and mediastinal disorders : Often : nasal congestion; rare :. pleural effusion, pleural fibrosis, pleural effusion, pulmonary fibrosis, shortness of breath digestive testosterone cypionate cycle system : Often : nausea, constipation, vomiting; Sometimes dry mouth, rarely :.

Diarrhea, abdominal pain, retroperitoneal fibrosis, ulceration of the gastrointestinal tract, gastrointestinal bleeding (black stool, blood in the vomit) Skin and subcutaneous tissue : Occasionally : allergic skin reactions, . hair loss From the musculoskeletal system and connective tissue : Sometimes : leg cramps. General disorders and reactions at the injection site : Sometimes : fatigue; rare : peripheral edema Very rare: in the case of abrupt withdrawal of Parlodel state of development, similar to the neuroleptic malignant syndrome. in the application of Parlodel in high doses (as well as other dopamine agonists) rarely observed reversible changes in sexual behavior, increased libido and hypersexuality, disappeared after dose reduction or discontinuation of treatment. The use of Parlodel for suppression of physiological lactation in the postpartum period in rare cases accompanied by the development of hypertension, myocardial infarction, seizures, stroke or mental disturbances.

In all cases, when the overdose occurred only parlodel deaths were observed. The maximum single dose taken Parlodel known to date is 325 mg. In case of overdose observed nausea, vomiting, dizziness, hypotension, postural hypotension, tachycardia, drowsiness, somnolence, lethargy, hallucinations.
If you accidentally taking Parlodel inside kids (isolated reports) noted the development of vomiting, fever and drowsiness. Improving the condition of patients occurred spontaneously or after a few hours of appropriate therapy. In case of overdose, it is recommended to take activated charcoal; possible to carry out gastric lavage immediately after ingestion.
Acute poisoning Treatment is symptomatic. For treatment of emesis or hallucinations can be assigned to metoclopramide.

Bromocriptine is both a substrate and inhibitor of CYP3A4 enzyme. Caution must be exercised with concomitant administration of bromocriptine and other inhibitors and / or substrates of CYP3A4 (azole antifungals, HIV protease inhibitors). Simultaneous treatment with macrolide antibiotics and Parlodel (erythromycin or josamycin) causes an increase bromocriptine plasma levels. Simultaneous application of octreotide and bromocriptine in patients with acromegaly is accompanied by increasing levels of the latter in the blood plasma.
Therapeutic effectiveness of bromocriptine, related to the stimulation of central dopaminergic receptors, may be reduced when using antagonists of dopamine receptors, such as antipsychotics (phenothiazines, butyrophenones and thioxanthine), and metoclopramide and domperidone.
Portability Parlodel may decrease the intake of alcohol.
Co-administration of Parlodel with antihypertensive drugs can lead to increased severity of blood pressure lowering.
Parlodel can be administered either as monotherapy or in combination with other antiparkinsonian drugs (both early and late stages of the disease). Combination with levodopa leads to increased antiparkinsonian action that often allows to reduce the dose of levodopa. The use of Parlodel in patients receiving treatment with levodopa, testosterone cypionate cycle especially useful with the weakening of the therapeutic effect of levodopa or developing complications such as abnormal involuntary movements (chorea-athetoid dyskinesia and / or painful dystonia), wasting syndrome effect by the end of the action of levodopa dose, the phenomenon of “vklyucheniya- off “(” on-off ‘) .